ARTICLE | Company News
ODAC to review Phase IV commitments
October 11, 2005 12:39 AM UTC
FDA's Oncologic Drugs Advisory Committee will meet on Nov. 8 to review the status of Phase IV trials of seven products that were granted accelerated approval. The products include Doxil doxorubicin fr...